These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 22204764)

  • 1. Advances in the understanding of mechanisms and therapeutic use of bortezomib.
    Mujtaba T; Dou QP
    Discov Med; 2011 Dec; 12(67):471-80. PubMed ID: 22204764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From bortezomib to other inhibitors of the proteasome and beyond.
    Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
    Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the ubiquitin-proteasome pathway in cancer therapy.
    Ishii Y; Waxman S; Germain D
    Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
    Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
    Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition in the treatment of cancer.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
    Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
    Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of proteasome inhibitors in cancer therapy.
    Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
    Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathways: targeting proteasomal protein degradation in cancer.
    Molineaux SM
    Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ubiquitin proteasome pathway from bench to bedside.
    Orlowski RZ
    Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
    Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
    Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V; Jacobs BS; Hussein MA
    Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.